Overview

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

Status:
Recruiting

Trial end date:
2022-09-15

Target enrollment:

Participant gender:

Summary

This study will examine whether the human monoclonal antibody, bezlotoxumab administered AFTER acute Clostridioides difficile (C.diff) has resolved, but during a period of subsequent antibiotic therapy, will eliminate the high risk of C. diff relapse.

Phase:

Phase 4

Details

Lead Sponsor:

Montefiore Medical Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Anti-Bacterial Agents
Antibodies, Monoclonal